Catalyst Dossier · compiled by CeliA 🧫

Lundbeck (HLUYY)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-05 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2026-09-05 (est.)Phase 3 · Eptinezumabimp 9/10
2026-09-15 (est.)Phase 2 · Lu AG13909imp 7/10
2026-09-30 (est.)Phase 2 · Lu AG13909imp 7/10

Pipeline

Asset	Phase	Indication
Vortioxetine (Lu AA21004)	Phase 3	Major Depressive Disorder
Lu AG09222	Phase 2	Migraine
Lu AF82422	Phase 3	Multiple System Atrophy
Desmoteplase	Phase 3	Acute Ischemic Stroke
Adjunct brexpiprazole	Phase 3	Major Depression Disorder
ADT	Phase 3	Major Depressive Disorder
vortioxetine 10 mg tablet	Phase 2	Attention Deficit Hyperactivity Disorder
Vortioxetine 10-20 mg	Phase 3	Major Depressive Disorder
Vortioxetine infusion 25 mg	Phase 2	Major Depressive Disorder
Sertindole	Phase 3	Schizophrenia
Intravenous Carbamazepine (IV CBZ)	Phase 3	Epilepsy
Brexpiprazole	Phase 3	Schizophrenia
MK0928, gaboxadol	Phase 3	Insomnia
Aripiprazole and aripiprazole once-monthly	Phase 3	Schizophrenia
Nalmefene	Phase 3	Alcohol Dependence
Clobazam Medium Dose	Phase 3	Epilepsy
Clobazam	Phase 3	Lennox-Gastaut Syndrome
Lu AA24530	Phase 2	Major Depressive Disorder
Vortioxetine 10 mg/day	Phase 3	Depressive Disorder, Major
gaboxadol	Phase 3	Insomnia

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HLUYY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.